Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28117055 | 0.98 | TSHR (0.34) | TSHRLAP3MEN1KMT2A | |
| SCHEMBL272769 | 0.89 | — | — | |
| Hydrogen Sulfide SCHEMBL28088448 | 0.87 | — | — | |
| SCHEMBL30560059 | 0.87 | — | — | |
| Sulfuric Acid SCHEMBL28098278 | 0.82 | TSHR (0.34) | TSHRMEN1KMT2ACA1CA2 | |
| Sulfuric Acid SCHEMBL4457624 | 0.82 | TSHR (0.34) | TSHRMEN1KMT2ACA1CA2 | |
| Ether SCHEMBL28837459 | 0.82 | TSHR (0.37) | TSHRMEN1KMT2ACA1CA2 | |
| Sulfuric Acid SCHEMBL4457625 | 0.81 | TSHR (0.33) | TSHRMEN1KMT2ACA1CA2 | |
| Vinyl Ether SCHEMBL28116801 | 0.80 | TSHR (0.36) | TSHRMEN1KMT2ACA1CA2 | |
| Thioglycolic Acid SCHEMBL4220070 | 0.79 | MEN1 (0.34) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842559-A2 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | Chimerix, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. | 2011-01-20 | — | — | US | disclosed |
| US-7517858-B1 | Prodrugs of pharmaceuticals with improved bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1865967-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | Chimerix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006110656-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX INC (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | CHIMERIX, INC. | 2007-01-04 | — | — | US | disclosed |
| WO-2006110656-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | CHIMERIX, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-0837630-A4 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | UNIV CALIFORNIA (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0837630-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015149-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS | ACE, CYP27A1, LIPC | TSHR 4740/4885LAP3 1217/4885MEN1 3708/4885 |
| US-20070003608-A1 | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | ACE, CYP27A1, LIPC | TSHR 4740/4885LAP3 1217/4885MEN1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.